vs
ALTISOURCE PORTFOLIO SOLUTIONS S.A.（ASPS）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是ALTISOURCE PORTFOLIO SOLUTIONS S.A.的1.5倍（$65.1M vs $42.3M），MESA LABORATORIES INC净利率更高（5.6% vs -16.8%，领先22.4%），MESA LABORATORIES INC同比增速更快（3.6% vs 3.2%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-525.0K），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 3.6%）
Altisource Portfolio Solutions S.A.是面向抵押贷款、房地产及消费金融领域的全球服务商，为贷款机构、服务商、投资者等市场参与者提供技术、数据与运营解决方案，优化资产管理、房产交易等业务流程，提升客户运营效率。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
ASPS vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.5倍
$42.3M
营收增速更快
MLAB
高出0.4%
3.2%
净利率更高
MLAB
高出22.4%
-16.8%
自由现金流更多
MLAB
多$18.5M
$-525.0K
两年增速更快
MLAB
近两年复合增速
3.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $42.3M | $65.1M |
| 净利润 | $-7.1M | $3.6M |
| 毛利率 | 26.5% | 64.2% |
| 营业利润率 | -15.5% | 12.2% |
| 净利率 | -16.8% | 5.6% |
| 营收同比 | 3.2% | 3.6% |
| 净利润同比 | 18.2% | 316.6% |
| 每股收益（稀释后） | $-1.02 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPSMLAB
| Q4 25 | $42.3M | $65.1M | ||
| Q3 25 | $41.9M | $60.7M | ||
| Q2 25 | $43.3M | $59.5M | ||
| Q1 25 | $43.4M | $62.1M | ||
| Q4 24 | $41.0M | $62.8M | ||
| Q3 24 | $40.5M | $57.8M | ||
| Q2 24 | $39.1M | $58.2M | ||
| Q1 24 | $39.5M | $58.9M |
净利润ASPSMLAB
| Q4 25 | $-7.1M | $3.6M | ||
| Q3 25 | $-2.3M | $2.5M | ||
| Q2 25 | $16.7M | $4.7M | ||
| Q1 25 | $-5.3M | $-7.1M | ||
| Q4 24 | $-8.7M | $-1.7M | ||
| Q3 24 | $-9.3M | $3.4M | ||
| Q2 24 | $-8.3M | $3.4M | ||
| Q1 24 | $-9.2M | $-254.6M |
毛利率ASPSMLAB
| Q4 25 | 26.5% | 64.2% | ||
| Q3 25 | 27.1% | 61.5% | ||
| Q2 25 | 30.1% | 62.0% | ||
| Q1 25 | 30.7% | 61.8% | ||
| Q4 24 | 30.3% | 63.3% | ||
| Q3 24 | 29.8% | 61.3% | ||
| Q2 24 | 32.5% | 64.0% | ||
| Q1 24 | 31.2% | 62.1% |
营业利润率ASPSMLAB
| Q4 25 | -15.5% | 12.2% | ||
| Q3 25 | 1.2% | 7.8% | ||
| Q2 25 | 7.5% | 5.1% | ||
| Q1 25 | 7.5% | 2.4% | ||
| Q4 24 | 1.4% | 9.2% | ||
| Q3 24 | 2.7% | 6.1% | ||
| Q2 24 | 5.3% | 9.6% | ||
| Q1 24 | -1.4% | -460.6% |
净利率ASPSMLAB
| Q4 25 | -16.8% | 5.6% | ||
| Q3 25 | -5.5% | 4.1% | ||
| Q2 25 | 38.5% | 8.0% | ||
| Q1 25 | -12.1% | -11.4% | ||
| Q4 24 | -21.3% | -2.7% | ||
| Q3 24 | -23.0% | 5.9% | ||
| Q2 24 | -21.1% | 5.8% | ||
| Q1 24 | -23.2% | -432.2% |
每股收益（稀释后）ASPSMLAB
| Q4 25 | $-1.02 | $0.65 | ||
| Q3 25 | $-0.22 | $0.45 | ||
| Q2 25 | $1.48 | $0.85 | ||
| Q1 25 | $-0.09 | $-1.30 | ||
| Q4 24 | $-4.72 | $-0.31 | ||
| Q3 24 | $-2.61 | $0.63 | ||
| Q2 24 | $-2.33 | $0.62 | ||
| Q1 24 | $-0.33 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $26.6M | $29.0M |
| 总债务越低越好 | $191.1M | $68.4M |
| 股东权益账面价值 | $-110.2M | $186.7M |
| 总资产 | $139.8M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资ASPSMLAB
| Q4 25 | $26.6M | $29.0M | ||
| Q3 25 | $28.6M | $20.4M | ||
| Q2 25 | $30.0M | $21.3M | ||
| Q1 25 | $30.8M | $27.3M | ||
| Q4 24 | $29.8M | $27.3M | ||
| Q3 24 | $28.3M | $24.3M | ||
| Q2 24 | $29.7M | $28.5M | ||
| Q1 24 | $29.6M | $28.2M |
总债务ASPSMLAB
| Q4 25 | $191.1M | $68.4M | ||
| Q3 25 | $192.5M | $69.4M | ||
| Q2 25 | $193.9M | $70.3M | ||
| Q1 25 | $195.0M | $71.3M | ||
| Q4 24 | $230.5M | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益ASPSMLAB
| Q4 25 | $-110.2M | $186.7M | ||
| Q3 25 | $-104.2M | $178.5M | ||
| Q2 25 | $-102.7M | $172.5M | ||
| Q1 25 | $-119.8M | $159.8M | ||
| Q4 24 | $-157.4M | $155.2M | ||
| Q3 24 | $-149.4M | $161.5M | ||
| Q2 24 | $-140.8M | $150.7M | ||
| Q1 24 | $-133.3M | $145.4M |
总资产ASPSMLAB
| Q4 25 | $139.8M | $434.8M | ||
| Q3 25 | $139.9M | $430.4M | ||
| Q2 25 | $142.9M | $435.7M | ||
| Q1 25 | $145.7M | $433.3M | ||
| Q4 24 | $143.6M | $433.3M | ||
| Q3 24 | $144.5M | $454.1M | ||
| Q2 24 | $146.6M | $440.4M | ||
| Q1 24 | $148.9M | $446.8M |
负债/权益比ASPSMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-505.0K | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $-525.0K | $18.0M |
| 自由现金流率自由现金流/营收 | -1.2% | 27.7% |
| 资本支出强度资本支出/营收 | 0.0% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $-5.1M | $37.9M |
8季度趋势，按日历期对齐
经营现金流ASPSMLAB
| Q4 25 | $-505.0K | $18.8M | ||
| Q3 25 | $718.0K | $8.2M | ||
| Q2 25 | $-306.0K | $1.9M | ||
| Q1 25 | $-5.0M | $12.7M | ||
| Q4 24 | $-1.4M | $18.1M | ||
| Q3 24 | $-1.6M | $5.3M | ||
| Q2 24 | $180.0K | $10.7M | ||
| Q1 24 | $-2.2M | $12.9M |
自由现金流ASPSMLAB
| Q4 25 | $-525.0K | $18.0M | ||
| Q3 25 | $697.0K | $7.1M | ||
| Q2 25 | $-309.0K | $884.0K | ||
| Q1 25 | $-5.0M | $11.9M | ||
| Q4 24 | $-1.4M | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率ASPSMLAB
| Q4 25 | -1.2% | 27.7% | ||
| Q3 25 | 1.7% | 11.7% | ||
| Q2 25 | -0.7% | 1.5% | ||
| Q1 25 | -11.5% | 19.2% | ||
| Q4 24 | -3.4% | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度ASPSMLAB
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.1% | 1.8% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.0% | 1.3% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | 0.0% | 1.5% | ||
| Q1 24 | 0.0% | 0.9% |
现金转化率ASPSMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | -0.02× | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPS
| Services | $39.9M | 94% |
| Revenue Relatedto Technology Platformsand Professional Services | $2.4M | 6% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
